Caligor Rx Managing Director Tammy Bishop Elected to Board of Directors for DA4S
News May 22, 2013
“It is a privilege to join the board of DA4S, and I look forward to contributing my knowledge and experience to help the organization achieve its strategic objectives,” said Bishop, whose term on the 16-member board runs through May 2017. “DA4S plays a vital role in championing the benefits of diversity within the life sciences community. I am eager to share the organization’s mission with leading life sciences companies across New England.”
“As the managing director of Caligor Rx, Tammy has demonstrated the strong, energetic and visionary leadership that supports DA4S’s mission to broaden supplier diversity across the entire life sciences community, including businesses and academic and government institutions,” said DA4S President Sylvester Wilkins. “Tammy ‘s more than 20 years of pharma industry experience and her unique entrepreneurial skills make her especially well suited to serve our board.”
Prior to joining Caligor Rx in 2010, Bishop worked in senior-level business development positions at Pharmarama and IDIS Pharmaceuticals. In addition, she served in senior corporate communications positions at OXiGENE, Gemini Genomics and Indevus Pharmaceuticals. In 2011, she was selected as a protégé for the DA4S Mentor Program and was instrumental in shepherding Caligor Rx’s national certification as a Woman-owned Business by the Women’s Business Enterprise National Council.
Bishop is a member of the Drug Information Association, Healthcare Distribution Management Association, Healthcare Women’s Business Association and Institute for Supply Chain Management. She received a Master’s Degree in Business Administration from the Simmons College School of Management.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE